AN2 THERAPEUTICS INC (ANTX) Stock Price & Overview
NASDAQ:ANTX • US0373261058
Current stock price
The current stock price of ANTX is 3.05 USD. Today ANTX is down by -8.68%. In the past month the price decreased by -40.08%. In the past year, price increased by 138.28%.
ANTX Key Statistics
- Market Cap
- 83.57M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.16
- Dividend Yield
- N/A
ANTX Stock Performance
ANTX Stock Chart
ANTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ANTX. When comparing the yearly performance of all stocks, ANTX is one of the better performing stocks in the market, outperforming 97.32% of all stocks.
ANTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANTX. While ANTX has a great health rating, there are worries on its profitability.
ANTX Earnings
ANTX Forecast & Estimates
6 analysts have analysed ANTX and the average price target is 1.02 USD. This implies a price decrease of -66.56% is expected in the next year compared to the current price of 3.05.
ANTX Groups
Sector & Classification
ANTX Financial Highlights
Over the last trailing twelve months ANTX reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 29.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.78% | ||
| ROE | -66.29% | ||
| Debt/Equity | 0 |
ANTX Ownership
ANTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.32 | 899.305B | ||
| JNJ | JOHNSON & JOHNSON | 20.72 | 581.198B | ||
| MRK | MERCK & CO. INC. | 23.71 | 304.549B | ||
| PFE | PFIZER INC | 9.12 | 156.259B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.39 | 120.559B | ||
| ZTS | ZOETIS INC | 16.95 | 50.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.35 | 27.632B | ||
| VTRS | VIATRIS INC | 5.42 | 15.624B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.3 | 11.733B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.859B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.705B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.077B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.14 | 4.454B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANTX
Company Profile
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
Company Info
IPO: 2022-03-25
AN2 THERAPEUTICS INC
1300 El Camino Real, Suite 100
Menlo Park CALIFORNIA 90501 US
CEO: Robert Corrigan
Employees: 22
Phone: 16503319090
AN2 THERAPEUTICS INC / ANTX FAQ
What does ANTX do?
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
What is the current price of ANTX stock?
The current stock price of ANTX is 3.05 USD. The price decreased by -8.68% in the last trading session.
What is the dividend status of AN2 THERAPEUTICS INC?
ANTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANTX stock?
ANTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the short interest for ANTX stock?
The outstanding short interest for AN2 THERAPEUTICS INC (ANTX) is 3.55% of its float.